| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
39,055 |
35,954 |
$1.99M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
24,684 |
22,618 |
$1.63M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
9,322 |
8,932 |
$705K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
11,933 |
11,542 |
$520K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
6,446 |
6,214 |
$406K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
4,239 |
3,968 |
$243K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,156 |
3,095 |
$224K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
7,852 |
7,512 |
$186K |
| 99215 |
Prolong outpt/office vis |
1,654 |
1,555 |
$160K |
| X5622 |
|
3,718 |
3,599 |
$157K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
8,564 |
8,305 |
$115K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,201 |
1,158 |
$112K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
3,344 |
3,231 |
$98K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,852 |
2,796 |
$95K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
5,585 |
3,340 |
$94K |
| 36415 |
Collection of venous blood by venipuncture |
22,080 |
20,300 |
$77K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
3,530 |
3,418 |
$66K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
797 |
783 |
$58K |
| 99188 |
|
5,720 |
5,597 |
$53K |
| 90461 |
|
1,421 |
1,379 |
$29K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
520 |
514 |
$24K |
| 92551 |
|
3,200 |
3,132 |
$21K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
3,379 |
2,738 |
$20K |
| 80053 |
Comprehensive metabolic panel |
2,032 |
1,959 |
$20K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,227 |
2,177 |
$19K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
688 |
680 |
$18K |
| 85027 |
|
3,169 |
3,050 |
$18K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,180 |
1,145 |
$17K |
| 80061 |
Lipid panel |
1,290 |
1,248 |
$16K |
| 90686 |
|
5,332 |
5,226 |
$16K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,288 |
2,143 |
$16K |
| 87650 |
|
945 |
915 |
$15K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,184 |
1,158 |
$14K |
| 99243 |
|
149 |
149 |
$12K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
309 |
248 |
$12K |
| 90480 |
|
535 |
523 |
$12K |
| 96127 |
|
2,560 |
2,485 |
$10K |
| 92567 |
|
1,125 |
1,078 |
$9K |
| 99000 |
|
669 |
641 |
$8K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
231 |
225 |
$8K |
| 92557 |
|
375 |
365 |
$8K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
214 |
209 |
$7K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
76 |
76 |
$6K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
217 |
210 |
$5K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
113 |
110 |
$5K |
| 81001 |
|
1,614 |
1,559 |
$5K |
| 99173 |
|
3,463 |
3,387 |
$5K |
| 90670 |
|
2,244 |
2,167 |
$4K |
| 87186 |
|
523 |
475 |
$4K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
532 |
513 |
$4K |
| 99442 |
|
144 |
90 |
$4K |
| 91320 |
|
44 |
40 |
$4K |
| 83970 |
|
106 |
102 |
$4K |
| 81025 |
|
465 |
446 |
$4K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
437 |
426 |
$3K |
| 82728 |
|
237 |
231 |
$3K |
| 82607 |
|
225 |
214 |
$3K |
| 87210 |
|
564 |
541 |
$3K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
101 |
101 |
$2K |
| 85018 |
|
1,112 |
1,071 |
$2K |
| 0071A |
|
61 |
52 |
$2K |
| 96161 |
|
1,115 |
1,040 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
204 |
160 |
$2K |
| 0072A |
|
47 |
46 |
$2K |
| 90715 |
|
106 |
106 |
$2K |
| 99421 |
|
157 |
155 |
$2K |
| 86803 |
|
112 |
111 |
$2K |
| 86780 |
|
89 |
89 |
$1K |
| 82565 |
|
349 |
345 |
$1K |
| 0054A |
|
29 |
29 |
$1K |
| 90656 |
|
605 |
593 |
$1K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
446 |
419 |
$1K |
| 0124A |
|
32 |
29 |
$1K |
| 84460 |
|
218 |
212 |
$978.41 |
| 87807 |
|
58 |
58 |
$787.72 |
| 90474 |
|
86 |
86 |
$774.97 |
| 92587 |
|
64 |
52 |
$732.12 |
| 99460 |
|
17 |
16 |
$691.90 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
71 |
65 |
$606.83 |
| 90662 |
|
13 |
13 |
$604.02 |
| 83655 |
|
51 |
51 |
$590.64 |
| 36416 |
|
186 |
156 |
$473.11 |
| 86140 |
|
83 |
82 |
$405.76 |
| 92550 |
|
34 |
25 |
$386.04 |
| 90677 |
|
320 |
300 |
$318.56 |
| 90473 |
|
12 |
12 |
$254.64 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
46 |
45 |
$244.14 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
61 |
59 |
$237.66 |
| 82040 |
|
71 |
69 |
$199.85 |
| 82746 |
|
13 |
13 |
$198.34 |
| 90680 |
|
990 |
948 |
$193.48 |
| 90723 |
|
1,223 |
1,182 |
$192.50 |
| 96381 |
|
17 |
15 |
$180.84 |
| T1013 |
Sign language or oral interpretive services, per 15 minutes |
15 |
14 |
$167.55 |
| 99441 |
|
27 |
14 |
$161.08 |
| 90688 |
|
83 |
81 |
$154.24 |
| 81003 |
|
151 |
144 |
$135.74 |
| 77080 |
|
12 |
12 |
$109.26 |
| 85652 |
|
35 |
28 |
$87.24 |
| 90707 |
|
28 |
27 |
$84.90 |
| 90648 |
|
1,923 |
1,859 |
$73.45 |
| 84550 |
|
12 |
12 |
$55.99 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
16 |
15 |
$14.50 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
42 |
39 |
$2.24 |
| 90696 |
|
28 |
28 |
$0.00 |
| 90381 |
|
32 |
27 |
$0.00 |
| 90697 |
|
149 |
134 |
$0.00 |
| 90651 |
|
42 |
42 |
$0.00 |
| 91317 |
|
44 |
43 |
$0.00 |
| 91318 |
|
92 |
88 |
$0.00 |
| 90716 |
|
29 |
28 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
14 |
13 |
$0.00 |
| 91319 |
|
12 |
12 |
$0.00 |
| 90685 |
|
273 |
268 |
$0.00 |
| 90710 |
|
12 |
12 |
$0.00 |
| 90734 |
|
53 |
51 |
$0.00 |
| 90633 |
|
508 |
504 |
$0.00 |